1. Home
  2. EIC vs LUNG Comparison

EIC vs LUNG Comparison

Compare EIC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

HOLD

Current Price

$11.33

Market Cap

293.8M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.51

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIC
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.8M
63.6M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
EIC
LUNG
Price
$11.33
$2.51
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$14.00
$6.81
AVG Volume (30 Days)
287.7K
1.1M
Earning Date
11-13-2025
11-12-2025
Dividend Yield
13.72%
N/A
EPS Growth
N/A
N/A
EPS
1.14
N/A
Revenue
$59,262,402.00
$91,664,000.00
Revenue This Year
$37.84
$9.21
Revenue Next Year
$23.33
$5.03
P/E Ratio
$10.00
N/A
Revenue Growth
44.30
15.59
52 Week Low
$10.81
$1.31
52 Week High
$16.39
$9.37

Technical Indicators

Market Signals
Indicator
EIC
LUNG
Relative Strength Index (RSI) 47.67 69.75
Support Level $11.00 $2.43
Resistance Level $11.44 $2.65
Average True Range (ATR) 0.22 0.21
MACD 0.05 0.05
Stochastic Oscillator 70.25 92.13

Price Performance

Historical Comparison
EIC
LUNG

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: